Clinical Research Directory
Browse clinical research sites, groups, and studies.
Sildenafil to Repair Brain Injury Secondary to Birth Asphyxia
Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre
Summary
The investigators will determine the maximum tolerable dose of sildenafil and establish the pharmacokinetic and pharmacodynamic profile of sildenafil in human asphyxiated neonates treated with hypothermia. They will use a 3+3 design to escalate the sildenafil dose up to 6 mg/kg/day (3mg/kg/dose q12h) in asphyxiated neonates demonstrating brain injury despite hypothermia treatment and assess whether we observe any beneficial effects of sildenafil on their brain and cardiopulmonary hemodynamics, without causing serious adverse events
Official title: Treatment of Neonatal Encephalopathy With Oral Sildenafil Suspension to Repair Brain Injury Secondary to Birth Asphyxia: An Open-label Dose-finding Clinical Trial (Phase Ib Study)
Key Details
Gender
All
Age Range
0 Days - 2 Days
Study Type
INTERVENTIONAL
Enrollment
20
Start Date
2019-09-19
Completion Date
2024-12
Last Updated
2024-07-12
Healthy Volunteers
No
Conditions
Interventions
Sildenafil Citrate
Cohort 1 of 3-6 neonates: 1st dose of 2mg/kg/dose, 2nd dose of 2.5 mg/kg/dose, and subsequent doses of 2.5mg/kg/dose q12h (= 5 mg/kg/day from dose #2) Cohort 2 of 3-6 neonates: 1st dose of 2mg/kg/dose, 2nd dose of 2.5 mg/kg/dose, 3rd dose of 3mg/kg/dose, and subsequent doses of 3mg/kg/dose q12h (= 6 mg/kg/day from dose #3) dose expansion phase in up to 5-15 asphyxiated neonates
Locations (1)
Montreal Children's Hospital
Montreal, Quebec, Canada